Home › Free Stock Grades › ZBIO
Zenas BioPharma, Inc. (ZBIO) Stock Grade
ZBIO · Healthcare
C
Market Cap
$1.7B
P/E Ratio
—
Revenue Growth (YoY)
+100.0%
Net Margin
-3777.4%
Return on Equity
—
Dividend Yield
None
About Zenas BioPharma, Inc.'s fundamentals
Zenas BioPharma is a biotechnology company with a $1.7 billion market capitalization that demonstrated strong revenue growth of 100% year-over-year, indicating expanding business activity. However, the company reported a substantial net loss in its latest annual statement, reflected in a negative net margin of -3777.4%, meaning it is currently unprofitable and spending significantly more than it generates in revenue. The company does not pay a dividend, which is typical for early-stage biotech firms focused on research and development rather than returning capital to shareholders.